Please login to the form below

Not currently logged in
Email:
Password:

The bulk of pharma digital spend fails to alter industry’s greenhorn status

Indegene’s Digital Maturity study reveals huge gaps in KPIs

Gaurav KapoorThe passage of the Health Information Technology for Economic and Clinical Health (HITECH) Act in 2009 paved the way for an evolving health IT revolution in the US and the adoption of multichannel marketing (MCM) to engage HCPs became almost ubiquitous.

The MCM maturity model was based on an amalgamation of seven components, namely content, channel and analytics, infrastructure, operations, organisation and culture. But the bulk of pharma’s digital spend remained concentrated in identifying channels of engagement, mostly slowing down ROI due to a lack of integration with the other six parameters. Consequently, and with few exceptions, the industry retains its ‘greenhorn’ status.

Pharma companies are certainly having to maintain a fine balance between delivering a great customer experience (Cx) and optimising their operational efficiency (Ox). While the voice of the customer (HCPs) helps gauge how efficient and effective the content being shared by the pharma companies is, operational excellence assesses their efficiency in channelising an organisation’s resources while also delivering great customer experience.

Cx ExcellenceOx Excellence

Contextualised - tailored content, hyper-segmented

Scalable - cover all channels, all markets

Measured - performance traction of content

Automated - Rapid, compliant and consistent

 

Intelligent -Data-driven content strategy

At the most nascent level of the digital maturity model, content production is decentralised to the extent that it is produced separately across different countries and channels. At this level, content analytics are out-of-the-box, that is, there are no set and consistent standards applied to the practices. There is no TMS in place, tags are hard-coded and there is no formalised media tracking process in place. The other major issue is the struggle with rates of automation. The least mature are those organisations that mostly use manual processes with only the least bit of automation. At the next level, organisations start using robotic process automation for individual tasks, but that still signals an urgent need for a unified approach.

The other end of the spectrum on the content maturity continuum envisions ‘content-on-demand’. The content at this stage of the maturity model is fully responsive and dynamic. With pre-set algorithms, the channel picks up the next best action, while the content is also tracked intelligently across the journey. As organisations become more digitally mature, multiple platforms evolve into a single platform of record at the enterprise level. There are enterprise-level media tagging naming conventions and enterprise-controlled processes for providing tagging and QA for media assets. At the most mature level, all technology as well as infrastructure enablers become increasingly adaptive and responsive to support new needs, thereby paving the way for end-to-end automation of content strategy, content deployment and content outcomes.

Pfizer, AstraZeneca and Merck fare well on the Cx scores, largely due to the relevance of content provided to HCPs on the go, while Pfizer, Amgen and AZ outscored others on the Ox scores with GSK getting a fair mention, according to a recent digital maturity study.

The diagnosis is clear - the closer the integration between the vertical and horizontal levers of digital maturity, the better the outcomes for all stakeholders in the healthcare value chain.

* Read: The Digital Maturity study

Gaurav Kapoor is co-founder and EVP of Indegene, a leading global healthcare solutions company

In association with

indegene

13th February 2018

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics